Suppr超能文献

检查适用于欧洲、美国和澳大利亚的生物药物(包括干细胞及其后代)的监管框架:第一部分——手动文献分析方法。

Examination of the regulatory frameworks applicable to biologic drugs (including stem cells and their progeny) in Europe, the U.S., and Australia: part I--a method of manual documentary analysis.

机构信息

Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.

出版信息

Stem Cells Transl Med. 2012 Dec;1(12):898-908. doi: 10.5966/sctm.2012-0037. Epub 2012 Dec 4.

Abstract

Recent development of a wide range of regulatory standards applicable to production and use of tissues, cells, and other biologics (or biologicals), as advanced therapies, indicates considerable interest in the regulation of these products. The objective of this study was to analyze and compare high-tier documents within the Australian, European, and U.S. biologic drug regulatory environments using qualitative methodology. Cohort 1 of the selected 18 high-tier regulatory documents from the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and the Therapeutic Goods Administration (TGA) regulatory frameworks were subject to a manual documentary analysis. These documents were consistent with the legal requirements for manufacturing and use of biologic drugs in humans and fall into six different categories. Manual analysis included a terminology search. The occurrence, frequency, and interchangeable use of different terms and phrases were recorded in the manual documentary analysis. Despite obvious differences, manual documentary analysis revealed certain consistency in use of terminology across analyzed frameworks. Phrase search frequencies have shown less uniformity than the search of terms. Overall, the EMA framework's documents referred to "medicinal products" and "marketing authorization(s)," the FDA documents discussed "drug(s)" or "biologic(s)," and the TGA documents referred to "biological(s)." Although high-tier documents often use different terminology they share concepts and themes. Documents originating from the same source have more conjunction in their terminology although they belong to different frameworks (i.e., Good Clinical Practice requirements based on the Declaration of Helsinki, 1964). Automated (software-based) documentary analysis should be obtained for the conceptual and relational analysis.

摘要

近年来,广泛的监管标准适用于组织、细胞和其他生物制品(或生物制剂)的生产和使用,作为先进疗法,表明人们对这些产品的监管非常感兴趣。本研究的目的是使用定性方法分析和比较澳大利亚、欧洲和美国生物药物监管环境中的高层文件。从欧洲药品管理局(EMA)、美国食品和药物管理局(FDA)和治疗商品管理局(TGA)监管框架中选择的 18 份高层监管文件的队列 1 进行了手动文件分析。这些文件符合人类生物药物制造和使用的法律要求,分为六类。手动分析包括术语搜索。在手动文件分析中记录了不同术语和短语的出现、频率和可互换使用情况。尽管存在明显差异,但手动文件分析显示,分析框架之间的术语使用存在一定的一致性。短语搜索频率的一致性不如术语搜索。总体而言,EMA 框架的文件提到了“药品”和“上市许可”,FDA 文件讨论了“药物”或“生物制剂”,而 TGA 文件则提到了“生物制剂”。虽然高层文件经常使用不同的术语,但它们共享概念和主题。尽管来自同一来源的文件属于不同的框架,但它们的术语更具一致性(即基于 1964 年赫尔辛基宣言的良好临床实践要求)。应获取自动(基于软件)文件分析,以进行概念和关系分析。

相似文献

4
2005 Donor Eligibility Requirements: Unintended Consequences for Stem Cell Development.
Stem Cells Transl Med. 2015 Oct;4(10):1097-100. doi: 10.5966/sctm.2015-0045. Epub 2015 Aug 18.
5
From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
Adv Drug Deliv Rev. 2015 Mar;82-83:192-6. doi: 10.1016/j.addr.2014.12.001. Epub 2014 Dec 7.
6
Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
Eur J Clin Pharmacol. 2019 Jan;75(1):1-11. doi: 10.1007/s00228-018-2542-1. Epub 2018 Sep 5.
7
Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Pharmacoepidemiol Drug Saf. 2015 Jul;24(7):709-15. doi: 10.1002/pds.3793. Epub 2015 May 27.
8
Strategies to facilitate adolescent access to medicines: Improving regulatory guidance.
Clin Trials. 2023 Feb;20(1):13-21. doi: 10.1177/17407745221132302. Epub 2022 Nov 5.
9
Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.
Ann N Y Acad Sci. 2017 Nov;1407(1):39-49. doi: 10.1111/nyas.13347. Epub 2017 Apr 26.
10
Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Clin Ther. 2012 Feb;34(2):400-19. doi: 10.1016/j.clinthera.2011.12.005. Epub 2012 Jan 13.

引用本文的文献

1
Global requirements for manufacturing and validation of clinical grade extracellular vesicles.
J Liq Biopsy. 2024 Nov 20;6:100278. doi: 10.1016/j.jlb.2024.100278. eCollection 2024 Dec.
2
Exosomes in the Real World of Medical Aesthetics: A Review.
Aesthetic Plast Surg. 2024 Jul;48(13):2513-2527. doi: 10.1007/s00266-023-03844-8. Epub 2024 Feb 5.
3
Challenges and strategy in treatment with exosomes for cell-free-based tissue engineering in dentistry.
Future Sci OA. 2021 Oct 28;7(10):FSO751. doi: 10.2144/fsoa-2021-0050. eCollection 2021 Dec.
4
Exosomal therapy-a new frontier in regenerative medicine.
Stem Cell Investig. 2021 Apr 2;8:7. doi: 10.21037/sci-2020-037. eCollection 2021.
5
Clinical applications for exosomes: Are we there yet?
Br J Pharmacol. 2021 Jun;178(12):2375-2392. doi: 10.1111/bph.15432. Epub 2021 May 3.
6
The potential roles of stem cell-derived extracellular vesicles as a therapeutic tool.
Ann Transl Med. 2019 Nov;7(22):693. doi: 10.21037/atm.2019.11.66.
7
Perspectives for Clinical Translation of Adipose Stromal/Stem Cells.
Stem Cells Int. 2019 May 2;2019:5858247. doi: 10.1155/2019/5858247. eCollection 2019.
9
Concepts in regenerative medicine: Past, present, and future in articular cartilage treatment.
J Clin Orthop Trauma. 2016 Jul-Sep;7(3):137-44. doi: 10.1016/j.jcot.2016.05.006. Epub 2016 Jun 15.
10
Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.
J Extracell Vesicles. 2015 Dec 31;4:30087. doi: 10.3402/jev.v4.30087. eCollection 2015.

本文引用的文献

3
Good Medical Practice or CanMEDS for education?
J Clin Pathol. 2012 Jun;65(6):565-7. doi: 10.1136/jclinpath-2011-200583. Epub 2012 Jan 28.
5
Qualitative environmental health research: an analysis of the literature, 1991-2008.
Cien Saude Colet. 2011 Oct;16(10):4239-55. doi: 10.1590/s1413-81232011001100030.
6
Regulatory scientific advice in drug development: does company size make a difference?
Eur J Clin Pharmacol. 2011 Feb;67(2):157-64. doi: 10.1007/s00228-010-0919-x. Epub 2010 Nov 4.
7
The systematic production of cells for cell therapies.
Cell Stem Cell. 2008 Oct 9;3(4):369-81. doi: 10.1016/j.stem.2008.09.001.
8
Methods for the thematic synthesis of qualitative research in systematic reviews.
BMC Med Res Methodol. 2008 Jul 10;8:45. doi: 10.1186/1471-2288-8-45.
9
(Re)defining biopharmaceutical.
Nat Biotechnol. 2008 Jul;26(7):743-51. doi: 10.1038/nbt0708-743.
10
To thwart disease, apply now.
Nature. 2008 Jun 12;453(7197):823. doi: 10.1038/453823a.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验